PD-L1 Inhibition With MPDL3280A in Bladder Cancer

Video

For High-Definition, Click

Immunotherapy has been utilized as a treatment for patients with prostate, bladder, and kidney cancer for several years, representing a proven paradigm, notes Robert Dreicer, MD. However, advances for patients with bladder cancer have been exceptionally slow, with the lack of an FDA approval in nearly 20 years.

Potentially transformative phase I data for the anti-PD-L1 therapy MPDL3280A in bladder cancer were presented at the 2014 ASCO Annual Meeting, explains Dreicer. The benefit seen in this study is particularly promising, given the overall poor prognosis for patients with this disease.

In the phase I trial, MPDL3280A was explored in 68 patients with metastatic urothelial bladder cancer who received prior chemotherapy. The objective response rate with MPDL3280A was 43% in PD-L1 positive patients (IHC 2/3). At the time of the data cut-off, 94% of patients had ongoing responses. The most common all-grade adverse events were decreased appetite (12%), fatigue (12%), and nausea (12%).

Based on these data, the FDA granted MPDL3280A a breakthrough therapy designation. A large phase II study is currently enrolling patients with metastatic urothelial bladder cancer. The study will have two cohorts, one for treatment-naive and the other for pretreated patients (NCT02108652).

Given the lack of available therapies for patients with bladder cancer, a well-conducted phase II study could be used for regulatory approval, believes Dreicer. The early breakthrough designation also bodes well for an early approval for MPDL3280A in bladder cancer, based on phase II data, suggests Omid Hamid, MD.

Related Videos
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Andrew Ip, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Arya Amini, MD
Adrianna Masters, MD, PhD,
Related Content
Lora Markley, Director of Regional Managed Care for The US Oncology Network

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

April 19th 2024
Article
FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022
Podcast
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article
Sorting Through Sexism, Guilt, and Motherhood in Medicine

Sorting Through Sexism, Guilt, and Motherhood in Medicine

January 27th 2022
Podcast
Ritu Salani, MD

Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy’s Entrance Into dMMR Endometrial Cancer

April 16th 2024
Article
Matthew Galsky, MD

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024
Article